Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly By: Benzinga via Benzinga June 27, 2014 at 15:49 PM EDT Merck (NYSE: MRK) paid a 230 percent premium for Hepatitis C-focused Idenix Pharmaceuticals (NASDAQ: IDIX). News of the massive ... Read More >> Related Stocks: Achison Inc Enanta Pharmaceutica Merck & Co